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The role of angiogenesis in pituitary tumor development has been questioned, as pituitary tumors have been usually found to be
less vascularized than the normal pituitary tissue. Nevertheless, a significantly higher degree of vasculature has been shown in
invasive or macropituitary prolactinomas when compared to noninvasive and microprolactinomas. Many growth factors and their
receptors are involved in pituitary tumor development. For example, VEGF, FGF-2, FGFR1, and PTTG, which give a particular
vascular phenotype, are modified in human and experimental pituitary adenomas of different histotypes. In particular, vascular
endothelial growth factor, VEGF, the central mediator of angiogenesis in endocrine glands, was encountered in experimental and
human pituitary tumors at different levels of expression and, in particular, was higher in dopamine agonist resistant prolactinomas.
Furthermore, several anti-VEGF techniques lowered tumor burden in human and experimental pituitary adenomas. Therefore,
even though the role of angiogenesis in pituitary adenomas is contentious, VEGF, making permeable pituitary endothelia, might
contribute to adequate temporal vascular supply and mechanisms other than endothelial cell proliferation.The study of angiogenic
factor expression in aggressive prolactinomas with resistance to dopamine agonists will yield important data in the search of
therapeutical alternatives.
1. Introduction
Theformation of newblood vesselswithin neoplasms, termed
angiogenesis, provides the tumor tissues with oxygen and
basic energetic compounds. An increase in tumor size nec-
essarily requires a corresponding increase in vascularization
that is assured by means of this complex dynamic process. In
most human tumors, including breast, bladder, and stomach,
angiogenesis has been shown to be correlated with tumor
behavior [1]. On the other hand, pituitary tumors have been
reported to be less vascularized than the normal pituitary
tissue [2–4], and differences in the angiogenic pattern of
pituitary adenomas have yielded highly controversial results
concerning hormonal phenotypes, size, or invasion. In most
studies, immunohistochemistry evaluation of differentmark-
ers ofmicrovascular density (MVD) such as cluster differenti-
ation molecules (CD31 and CD34), Factor VIII (factor eight-
related antigen), and Ulex europaeus agglutinin I has been
used. Nevertheless, the appraisal of MVD by immunohisto-
chemistry has a number of substantial limitations, which are
mainly due to the complex biology of tumor vasculature, and
the irregular geometry of the vascular system [5].
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Nevertheless, accumulating evidence points to increased
angiogenesis in pituitary adenomas. For example, it has been
described that macroprolactinomas are significantly more
vascular than microprolactinomas [3], and Turner et al.
demonstrated a significantly higher degree of vasculature of
invasive pituitary prolactinomas [6]. Inhibitors of angiogene-
sis were effective in the suppression of growth of experimental
prolactinomas [7] and, besides, in angiographic studies, the
presence of additional arteries (which were not part of the
portal system) was found in 66% of patients with pituitary
adenomas [8].
Even so, the role of angiogenesis in pituitary tumor
development has been questioned, as the normal pituitary is
a highly vascularized gland.
In this review we summarize data on angiogenesis in
human pituitary adenomas, as well as in two mouse models
of dopamine agonist resistant prolactinomas: the dopamine
D2 receptor (D2R) knockout mouse (Drd2−/−) [9] and
the lactotrope specific D2R knockout mouse (lacD2RKO)
generated by Cre LoxP technology [10].
2. Angiogenic Factors in Human
Pituitary Adenomas
2.1. Vascular Endothelial Growth Factor. Vascular endothelial
growth factor-A (VEGF-A or VEGF) is a central regulator of
angiogenesis. It is the founding member of a family of closely
related cytokines that exert critical functions in vasculoge-
nesis and in both pathologic and physiologic angiogenesis
and lymphangiogenesis. The VEGF-A gene is located on the
short arm of chromosome 6 and is differentially spliced to
yield several different isoforms, the three most prominent of
which encode polypeptides of 189, 165, and 121 amino acids in
human cells. The protein has a hydrophobic leader sequence
and typical of secreted proteins. It was discovered in the
late 1970s as a tumor-secreted protein that potently increased
microvascular permeability to plasma proteins. It is essential
for normal developmental vasculogenesis and angiogenesis,
as both null (VEGF-A−/−) and heterozygote (VEGF-A+/−)
animals are embryonic lethals. It increases vascular perme-
ability to plasma and plasma proteins, a characteristic trait
of the tumor microvasculature and a critical early step in
tumor stroma generation. It is a selectivemitogen for vascular
endothelium because its major tyrosine kinase receptors are
selectively (though not exclusively) expressed on vascular
endothelium, and furthermore, it is overexpressed in a variety
of human cancer cells (in human vascular tumors, includ-
ing brain, colon, gastrointestinal tract, ovary, and breast)
[1].
Type 2 VEGF receptor (VEGFR2) is the major positive
signal transducer for both physiological and pathological
angiogenesis induced by VEGF. It is a highly active kinase
receptor and triggers a broad spectrum of signaling cascades.
The phosphoinositide 3-kinase (PI3K) signal transduction
pathway leading to phosphorylation of protein kinase B
(AKT) has emerged as one of the main signal routes of
VEGFR2 activation [11]. Indeed, many experiments using in
vivo and in vitro systems have demonstrated that activation
of PI3K by VEGFR2 promotes endothelial cell survival,
proliferation, and angiogenesis, and the overexpression of
a dominant-negative form of AKT blocks the survival effect
of VEGF [12].
2.2. Vascular Endothelial Growth Factor in the Pituitary
Gland. The pituitary contains abundant VEGF as well as
VEGFR2 [13, 14], and VEGF participates in the formation
of the vascular network of a new pituitary tumor [15, 16].
It is also involved in the proliferative action of estrogen on
lactotrophs [17], and increased tumoral VEGF expression
was observed during estrogen-induced prolactinoma devel-
opment in rats [18]. These data indicate that even though
the role of angiogenesis in pituitary adenomas is contentious,
VEGF might contribute to adequate temporal vascular
supply.
VEGF expression has been described in all cell types
in the normal pituitary, with greater expression in soma-
totrope and follicle-stellate cells. Using immunohistochem-
istry, higher VEGF expression has been shown in the normal
human pituitary gland compared with adenomas [19], while
the opposite has also been published [20]. In a group of
ACTH and GH secreting adenomas, pituitary carcinomas
had the strongest VEGF immunoreactivity, and furthermore,
VEGF expression was related to suprasellar extension [19].
It was also described that VEGF and KDR expression were
expressed more on tumors with extrasellar growth than
intrasellar ones, suggesting they could be markers for poor
outcome after partial tumor resection [21].On the other hand,
Viacava et al. [20] found no differences in VEGF expression
among tumors of different histotypes, and McCabe et al.
comparing VEGF in a series of adenomas composed of 77%
nonfunctioning adenomas and only 4% of prolactinomas
found the highest expression in nonfunctioning adenomas
and GH producing adenomas [22]. Elevated serum VEGF
concentrations have been demonstrated in patients harbor-
ing pituitary tumors, and approximately 90% of human
pituitary tumors cultured in vitro show measurable VEGF
secretion.
In a cohort of pituitary adenomas we found that VEGF
protein expression was higher in dopamine agonist resistant
prolactinomas compared to nonfunctioning GH and ACTH
secreting adenomas [23]. This finding may be related to
the high percentage of macroprolactinomas in the series
studied, as it has been described that macroprolactinomas
are significantly more vascularized than microprolactino-
mas. Furthermore, lower VEGF found in ACTH-producing
adenomas may be consistent with the finding that VEGF
production can be suppressed by glucocorticoids which are
potent inhibitors of VEGF production in vitro [24].
Most studies reveal that sex, age, or even rate of recur-
rence does not influence VEGF expression in pituitary
tumors.
Cyclin-dependent kinase 5 (CDK5) regulates the activi-
ties of various proteins and cellular processes in the nervous
system and is present in normal human pituitary and in
pituitary tumors. It has been shown that increased CDK5-
mediated VEGF expression might play a crucial role in
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the development of pituitary adenomas.These results suggest
that roscovitine and other CDK5 inhibitors could be use-
ful as antiangiogenic drugs in invasive pituitary adenomas
[25].
These data indicate angiogenesis in the pituitary tumors,
as well as in other endocrine neoplasms, probably reflects
the basic observation that tumors require neovascularization
to grow; however, the changes that occur may be somewhat
different from some other tissues that are less vascularized
in the nonneoplastic state. Some data suggest that VEGF
may prolong cell survival by inducing expression of the
antiapoptotic protein bcl-2 in pituitary adenomas, suggesting
that part of its angiogenic activity is related to protection
of endothelial cells from apoptosis. VEGF has also been
associated with intratumoral hemorrhage [26] and might
also participate in the occurrence of pituitary peliosis, a
form of vasculogenic mimicry. Peliosis may be linked to the
permeabilizing function of this growth factor, and to the
increased fenestration induced in blood vessels stimulated by
VEGF overexpression. Peliosis occurrence has been related
to high VEGF expression in hepatocarcinogenesis, spleen
damage, and in a lethal hepatic syndrome in mice. This
process may be seen in prolactinomas and other pituitary
adenomas, though it usually goes unrecognized.
2.3. Fibroblast Growth Factor-2. Another potent angiogenic
factor is basic fibroblast growth factor-2 (basic FGF, or
FGF2). It was originally isolated from the bovine pituitary
and has a pleiotropic activity affecting both vasculature and
parenchyma cell proliferation and differentiation [27]. It
belongs to a large family of heparin-binding growth factors
comprising at least 22 structurally related members. FGF2
expression is complex; at least four FGF2 isoforms (18, 22,
22.5, and 24 kDa) in human and three (18, 21, and 22 kDa) in
mouse are synthesized through alternative translation initia-
tion fromCUG codons.The 18 kDa isoform is predominantly
cytoplasmic but can also be found in the extracellular matrix,
while the higher-molecular-weight isoforms are localized in
nuclei and ribosomes. The 18 kDa FGF2 isoform is highly
expressed in the normal human pituitary, while pituitary
adenomas produce predominantly the 24 kDa form [28].
More recently, a 34 kDa isoform was reported, with the most
upstream CUG codon among all FGF2 forms [29]. None of
the isoforms have a typical secretory signal sequence, but
alternative pathways have been described for their export
from the cell.
The biological effects of FGF2 are mediated through
four high-affinity transmembrane receptors (FGFR1–FGFR4)
that have intrinsic tyrosine kinase activity [30]. They can be
found on a wide variety of cell membrane surfaces including
endothelial cells where FGF2 exerts its proangiogenic func-
tions.
2.4. Fibroblast Growth Factor-2 and FGFR1 in the Pituitary.
FGF2 participates in pituitary development and proliferation
and regulates hormone synthesis and secretion, affecting
prolactin and TSH production. It is mainly produced
by folliculostellate cells [31], although somatotropes and
gonadotropes have also been reported to be sources of this
growth factor.
FGF2 participates in estradiol-mediated prolactinoma
induction in rats under both physiological and pharma-
cological conditions [32–34]. FGF2 is also expressed by
human pituitary adenoma cells in vitro, and high lev-
els of serum FGF2 were found in patients bearing pitu-
itary tumors, declining following surgical adenomectomy
[35].
In the case of a giant invasive prolactinoma with loss
of response to dopamine agonist therapy we have reported
strong immunoreactivity for both angiogenic factors VEGF
and FGF2, as well as immunoreactivity for the endothelial cell
marker CD31 indicating high vascularization of the adenoma
[36].
FGFR1 is found in the normal human pituitary as well
as in pituitary adenomas, and its mRNA was described in
the rat neural and anterior lobe. Furthermore, FGFR1 has
been proposed as a candidate marker of pituitary tumors
together with FGF2 and pituitary tumor transforming gene
(PTTG); indeed, the FGF2 receptor FGFR1 was found to be
highly expressed in pituitary tumors compared to the normal
gland [37]. Furthermore, significantly increased Fgfr1mRNA
expression was described in functioning tumors that invaded
the sphenoid bone compared with those that did not, thus
raising the possibility of using the FGFR1 as a molecular
marker of tumor biological behavior [37]. On the other
hand, it has also been determined that cytoplasmic FGFR1
immunoreactivity was inversely correlated with maximum
pituitary tumor diameter [38].
Some proteins and genes related to FGF-2 have been
linked to the development of prolactinomas such as FGF-4,
PTTG, thrombospondin, FGF2 antisense RNA, or truncated
FGFR4.
FGF4. DNA derived from human prolactinomas codifies for
transforming activity in heterologous cells and has sequences
in close resemblance with those of hst gene. Overexpression
of hst gene leads to increased production of FGF4. Shimon
et al. [39] demonstrated the function of the hst gene in rat
lactotrope tumor formation and prolactin secretion. They
were able to show that lactotropes in 5 of 14 prolactinomas
stained strongly with anti-FGF-4 monoclonal antibodies,
and the immunoreactive hst product in adenoma cells was
observed in invasive prolactinomas [40]. These findings
imply a role of hst gene, and its product FGF4, in cellular
proliferation, growth, and aggressive behavior in prolactino-
mas.
PTTG. Pituitary tumor transforming gene (Pttg), located on
chromosome 5q33, has been shown to be tumorigenic in
vivo, by regulating FGF2 secretion and inhibiting chromatid
separation [41, 42]. Estrogen promotes experimental pro-
lactinoma development via induction of a pituitary tumour
transforming gene (pttg) [43]. Patients with prolactinomas
which were responsive or unresponsive to dopamine agonists
had similar pituitary PTTGmRNA levels [43].
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Recently ameta-analysis suggested that PTTG expression
may be associated with tumor invasiveness and microvessel
density of pituitary adenomas [44].
Thrombospondin-1. TSP-1 is a modular glycoprotein secreted
by different cell types, including endothelial cells. It is com-
posed of multiple active domains that bind to soluble factors,
cell receptors, and extracellular components. TSP-1 was the
first endogenous inhibitor of angiogenesis to be identified
and its effect is due, at least in part, to its capacity to bind
FGF2 [45]. TSP-1 is reduced in estrogen induced pituitary
adenomas [46] and TSP-1 agonists can inhibit experimental
prolactinoma development and angiogenesis in rats [46, 47].
FGF2 Endogenous Antisense (GFG) RNA.In Xenopus laevis
oocytes, a 1.5 kb FGF2 antisense (GFG) RNA complementary
to the third exon and 3󸀠UTR of FGF-2mRNAhas been impli-
cated in FGF2 mRNA regulation. The human homolog has
been localized to the same chromosomal site as FGF2 (chro-
mosome 4, JO4513 adjacent to D4S430), confirming this as a
human endogenous antisense gene. This GFG antisense gene
also encodes a 35 kDa protein and regulates cell proliferation
and hormone secretion. Pituitary tumors have been shown
to express FGF2; GFG protein levels are higher in the normal
gland than in most tumors, and aggressive pituitary adeno-
mas appear to express more FGF-2 than GFG mRNA [48].
Truncated FGFR4. Altered FGF receptor expression has been
found in pituitary adenomas [48], and FGFR4 undergoes
alternative transcription initiation in pituitary adenomas,
giving rise to an oncogenic protein in pituitary adenomas of
various subtypes. Expression of this pituitary tumor-derived-
(ptd-) FGFR4 protein is more frequent in macroadenomas
than inmicroadenomas and correlateswith theKi-67 labeling
index. Some data suggest that ptd-FGFR4 alters cell adhesion
by a mechanism that explains the loss of reticulin, which is
the hallmark of pituitary adenomas.
Taken together, these data suggest that deregulated
FGF/FGFR system function plays a role in pituitary tumori-
genesis and particularly in prolactinoma development.
2.5. Markers of Vascular Development in Pituitary Tumors:
CD31, CD34, Endocan, and Nestin. Different markers of
microvascular density (MVD) such as CD31 and CD34,
FactorVIII (factor eight-related antigen), andUlex europaeus
agglutinin I, and nestin have been used to evaluate angiogen-
esis.
CD31 and CD34, both endothelial cell antigens, are
sensitive markers of microvessels. They stain the majority of
tumor vessels, both mature and new vessels. Even though
antibodies to CD31 are not completely specific for endothelial
cells, as theymay also detect plasma cells, they arewidely used
for MVD appraisal, and results generally correlate with those
obtained with CD34. Using these endothelial cell markers,
some authors have found more prominent vasculature in
prolactinomas, and others found that these tumors had
the lowest while TSH secreting adenomas had the highest
MVD [49]. It has also been reported that ACTH secreting
tumors had the lowest MVD [4, 50], while other authors
found that GH secreting adenomas had the lowest [3, 51, 52]
or the highest MVD [4]. Finally, some authors did not find
any significant difference in MVD between the hormonal
subtypes [20, 53]. These results point to the complexity of
evaluation of vascularity in the adenomatous pituitary.
Interestingly, we described a high correlation of VEGF
and CD31 expression for prolactinomas and nonfunctioning
adenomas [23]. The strong positive association of VEGF and
CD31 expression found in human pituitary adenomas sug-
gests the participation of tumor vascularization in adenoma
development. Even so, this is in contrast to results published
by other authors in whichMVD did not correlate with VEGF
expression.
Furthermore, Endocan, a newmarker of vascular endoth-
elial cells from cancers and closely related to tumor angio-
genesis, is exclusively expressed in CD34-positive vascular
endothelial cells in pituitary adenomas and significantly
elevated in macroadenomas compared with microadenomas
[54].
On the other hand, proliferation markers (PCNA and
Ki67) do not correlate with the angiogenic markers CD31 and
VEGF, as described by us and others [5, 49, 52, 55–57]. This
suggests that the rate of epithelial and tumor cell proliferation
in pituitary tumors is not directly related to neovasculariza-
tion, and other factors, such as primary genetic alterations
or alteration of apoptotic pathways, may directly affect the
rate, invasiveness, and tumor behavior. To this respect, a
positive relationship was observed, between the expression
of bcl-2, an antiapoptotic protein, and increasing MVD sug-
gests an association between angiogenesis and cell survival
[56, 58].
In a recent work we found that adenomas had a lower
vascular area compared to normal pituitary tissue, but, inter-
estingly, pituitary adenomas had significantly more small
vessels than control pituitaries [59].
Low vascularization is a peculiar situation for tumors
despite their benign nature, as even premalignant lesions like
precarcinomas of the cervix and breast have increased MVD
[60, 61]. However, some benign tumors that hardly ever
progress to malignancy were reported with lower vascular
density when compared to normal tissue [62–64]. Never-
theless, even though vascular area was lower in pituitary
tumors compared to the normal gland, vessel size proportion
was markedly different in the normal and tumoral pituitary.
This suggests that the increased percentage of small vessels
in adenomas may be the predominant feature associated
with angiogenesis. In accordance with our results, Itoh et al.
suggested that angiogenesis in the tumoral pituitary may
occur with changes in diameter and shape of blood vessels
[50].
With regard to the relation between MVD and sex or
age of the patients, contradictory findings have also been
reported. Jugenburg et al. [3] reported no significant corre-
lations, whereas Turner et al. [6] found tumor MVD clearly
decreased with age in GH producing adenomas, and there
was a trend in other tumor types from older patients to
have lower MVD. In contrast, a positive correlation between
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age and MVD has also been reported. We described that,
in pituitary adenomas, CD31 expression was not different
between sexes and did not correlate with patients’ age
when all adenomas were considered. Nevertheless, if only
nonfunctioning adenomaswere analyzed, we found a positive
correlation of CD31 with increasing age [23], in agreement
with other authors [52], and therefore age may have an influ-
ence on the extent of neovascularization of nonfunctioning
adenomas.
An additional reliable marker of neovascularization is
nestin. It is a class VI intermediate filament protein that
participates in cytoskeleton formation and has been found in
endothelial cells of newly formed blood vessels of developing
organs [65]. It was originally described as a neuronal stem/
progenitor cell marker in cells of the developing central
nervous system [66]. In particular, it has been reported
that nestin-containing cells in the pituitary gland play an
important role in its cellular and morphological plastic-
ity throughout life [67]. Moreover, nestin expression was
detected in endothelial cells of pituitary adenomas and in a
carcinoma sample [68].
We found that nestin expression was evidenced only in
the adenomatous pituitaries and correlated positively with
the percentage of small vessels and negatively with years
since the first diagnosis of pituitary adenoma [59]. Nestin has
been detected in various neoplasms such as astrocytomas and
malignant gliomas, including glioblastoma multiforme [69]
and prostate cancer [70]. In these tumors it was generally
expressed in immature endothelial cells generated in the
course of angiogenesis [65, 71] and in the adult human
pancreas nestin localized in endothelial cells predominantly
of small caliber [72]. In our cohort of adenoma samples
nestin localizedmainly associated with blood vessels, and the
inverse correlation of nestin with years of tumor evolution
or large blood vessels may suggest that nestin is expressed
mainly in the setting of angiogenesis, and not in the quiescent
endothelium, as previously suggested for other neoplasms
[73]. Small vessels probably represent the newly formed blood
vessels during pituitary adenoma generation. Indeed, nestin
expression was evidenced only in newly formed capillaries
growing into the infarcts and not in the necrotic capillaries,
during pituitary infarction or apoplexy [74].
Therefore, this stem cell marker may be associated with
endothelial cell development in pituitary adenomas.
2.6. Dopamine D2 Receptors. A relationship between D2Rs
and endothelial cell proliferation within tumors has been
proposed. Dopamine and other related catecholamine neu-
rotransmitters that interact with the D2R selectively inhibit
VEGF-induced angiogenesis and inhibit the growth ofmalig-
nant tumors as well as the vascular permeabilizing and
angiogenic activities of VEGF [75]. Besides, in two outbred
lines ofWistar rats, which present high and lowdopaminergic
reactivity, respectively, VEGF expressionwas lower in the first
group, and this group was more resistant to tumor implanta-
tion and developed significantly fewer lung metastases [76].
These data, as well results obtained in animal models,
indicate that the D2R is linked to pituitary VEGF expression.
In dopamine agonist resistant prolactinomas a decrease in
number or function of D2Rs has been proposed [77], and we
have found highly expressed VEGF in a dopamine agonist
resistant giant prolactinoma [36], as well as in a cohort of
dopamine agonist resistant macroprolactinomas [23].
3. Mutant Animal Models of Dopamine
Agonist Resistant Prolactinomas
Prolactin secreting adenomas are the most frequent type
among pituitary tumors. Patients usually present endocrino-
logical symptoms resulting from hyperprolactinemia and,
less commonly, in the case of macroprolactinomas, they
have visual defects due to compression of the optic chiasm.
Macroprolactinomas are benign, slowly proliferating tumors,
although they may be locally highly aggressive, particularly
in males, and invade adjacent structures. Giant prolacti-
nomas (tumor volume exceeding 4 cm in diameter and/or
with prolactin levels higher than 3000 ng/mL and mass
effect), a rare subcategory of macroprolactinomas, remain
one of the greatest challenges in neurosurgery. Because of
invasive growth, giant adenomas can compress or destroy
adjacent structures, resulting in neurological dysfunction and
cavernous sinus compression. D2Rs are found in pituitary
lactotropes, where they mediate the tonic inhibitory control
that dopamine exerts on prolactin synthesis and release, and
therefore pharmacological therapy with dopamine agonists
remains the mainstay of treatment. This therapy is effec-
tive in more than 85% of patients with prolactin-secreting
pituitary tumors. A minority of patients show no primary
response to either bromocriptine or cabergoline [78], and the
development of dopamine agonist resistance in an initially
responsive prolactinoma is unusual. A decrease in number
or function of D2Rs has been proposed in dopamine agonist
resistance [79, 80]. In these cases, tumors tend to be invasive
and aggressive andmay require extirpation [78]; therefore, an
alternative target would be desired.
The physiological significance of dopamine inhibitory
control in lactotrope proliferation and secretory activity
has been appreciated in mice lacking D2Rs generated by
targeted mutagenesis (Drd2−/−) [9]. Female Drd2−/− mice
have pituitary hyperplasia, chronic hyperprolactinemia, and
provide an experimental model for dopamine agonist resis-
tant prolactinomas [81]. In Drd2−/− mice highly vascularized
adenomas develop after 16 months of age, especially in
females, but also in males [82].
Analysis of Drd2−/− mice also revealed the unexpected
importance of D2Rs in the regulation of the growth hormone
(GH) axis and control of body size, a differential phenotype
that is considerable in males.Drd2−/− mice display a shortfall
of pituitary somatotropes and reduced GH and IGF-I serum
levels and are dwarfs [83, 84]. Somatotrope shortfall and
dwarfism of Drd2−/− mice are related to the lack of central
D2Rs which regulate growth hormone-releasing hormone
or somatostatin function [85]. Therefore, by conducting a
functional dissection strategy based on cell-specific Drd2
inactivation in lactotropeswe developed a strain of transgenic
mice expressing cre from a mouse prolactin gene promoter,
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Tg(Prl-cre)1Mrub to eliminate D2Rs from pituitary lactotropes
(LacDrd2KO). LacDrd2KO female mice exhibit chronic
hyperprolactinemia, marked pituitary hyperplasia, and a
preserved GH axis and therefore provide a cleaner mutant
model to study the generation and regulation of dopamine
agonist resistant prolactinomas without the confounding
effect of central D2Rs.
4. Angiogenic Factors in Mouse Models of
Dopamine Agonist Resistant Prolactinomas
4.1. VEGF. D2R knockout (Drd2−/−) mice generated by
targeted mutagenesis and lacDrd2KOmice, generated by Cre
LoxP technology, have chronic hyperprolactinemia, pituitary
hyperplasia, and provide experimental models for dopamine
agonist resistant prolactinomas [10, 81]. In Drd2−/− mice
highly vascularized adenomas develop after 16 months of
age, especially in females, but also in males [82]. Prominent
vascular channels, as well as extravasated red blood cells
not contained in capillaries or peliosis, are common findings
in the hyperplastic and adenomatous Drd2−/− pituitaries.
Peliosis has been found in different tumors that secrete
VEGF. In accordance, VEGF mRNA and protein expres-
sion are increased in pituitaries from Drd2−/− female mice
[86]. In lacDrd2KO female mice hyperplastic pituitaries also
showed enhanced vascularization and VEGF content, with
no shortfall of somatotropes, as in the global knockout
model [10]. These results support the notion that defective
function of lactotrope D2Rs increases VEGF expression
and may participate in pituitary angiogenesis of prolactino-
mas.
Pituitary VEGF production is stimulated by estrogen
in rat pituitaries and the somatolactotrope cell line GH3.
Nevertheless, estrogen levels are not increased in Drd2−/−
or lacDrd2KO female mice, indicating that increased pitu-
itary VEGF expression is mainly dependent on the lack of
dopaminergic control. In experiments with wild-type female
mice we found that prolonged treatment with the D2R
antagonist, haloperidol, enhanced pituitary VEGF protein
content and prolactin release [86], and there was a signifi-
cant correlation between pituitary VEGF levels and serum
prolactin after haloperidol treatment. These results support
the notion that dopamine acting at the D2R inhibits pituitary
VEGF expression.
Interestingly, we found that the main source of VEGF in
the hyperplastic pituitary was follicle stellate cells and not
lactotropes [86]. Follicle stellate cells represent 5 to 10% of
pituitary cells and are an important component of paracrine
communication within the pituitary. They are detected by
their content of the glial protein S100, and they form follicles,
are star shaped, and have long processes in between the
secretory cells of the pituitary. They also contain FGF-
2, follistatin, and interleukin 6. Because D2Rs have been
described in lactotropes and not in follicle stellate cells, it may
be inferred that a paracrine-derived factor from lactotropes
is acting on follicle stellate cells to increase VEGF expression
(Figure 1).
4.2. FGF2. In the hyperplastic pituitaries of Drd2−/− mice,
FGF-2 promoted prolactin secretion and cellular prolifera-
tion, and, interestingly had a differential subcellular distribu-
tion compared to that of wild-type pituitaries, which could
be associated with different biological roles of this angiogenic
factor in both genotypes [87]. Nevertheless, pituitary FGF2
content was not increased in this model.
4.3. PTTG. When compared to female wild-type mice,
pituitaries from female Drd2−/− mice had decreased PTTG
concentration [43]. PTTG did not correlate with prolactin
levels or tumor size in animal models of prolactinoma,
and its pituitary content was not related to a decrease in
dopaminergic control of the lactotrope, but it was positively
influenced by estrogen action at the pituitary level [43].
Taken together these results suggest that angiogenesis of
pituitary tumors in the Drd2−/− mice does not depend on
FGF-2 and PTTG expression. Instead, the development of
new blood vessels seems to be dependent on VEGF, which
is increased due to the absence of dopaminergic control
(Figure 2).The pattern of expression of the angiogenic factors
would determine the angiogenic phenotype of the prolactino-
mas and probably reflect the benign nature and slow growth
rate of these tumors, compared to highly aggressive tumors
such as melanoma in which most of the angiogenic factors
are upregulated.
5. Antiangiogenesis in Pituitary Tumors
VEGF and its receptormay become supplemental therapeutic
tools in dopamine-resistant prolactinomas. In this regard, in
recent years, antiangiogenesis has been publicized as a novel
alternative or supplement to conventional cancer therapy, and
a variety of regimens that prevent tumor angiogenesis and/or
that attack tumor blood vessels have met with remarkable
success in treating mouse cancers [88]. There has been a
great interest in the targeting of tumor vasculature and
the development of antiangiogenic agents, which interrupt
tumor’s supply of oxygen and nutrients. Treatment with anti-
VEGF antibodies significantly inhibited growth of several
tumor cells lines and has been approved by the FDA for a
combinatorial treatment with chemotherapy for metastatic
colorectal cancer, nonsmall-cell lung cancer,metastatic breast
cancer, andmore recently glioblastomamultiforme and renal
cell carcinoma [89]. However not all trials have been positive
[90, 91], indicating that individual characteristics of different
tumors should be studied. Furthermore, resistance to anti-
VEGF therapies develops after some months of treatment in
most patients. Therefore, despite the spectacular successes
reported in the treatment of mouse tumors, the first clinical
trials were discouragingly negative. This could be related to
the fact that most of the patients treated in the beginning
had advanced disease and had already failed conventional
treatments. Also, antiangiogenesis therapy differs fundamen-
tally from chemotherapy, and optimal implementation is still
needed.
In Drd2−/− female mice using two strategies with anti-
VEGF compounds we demonstrated that VEGF is required








Figure 1: Disruption of the D2R from lactotropes induces paracrine VEGF secretion from follicle stellate cells. VEGF acts on VEGFR2
















Figure 2: Total (Drd2−/−) or lactotrope (LacDrd2KO) disruption of D2R evokes and increases in pituitary VEGF andCD31, with no alteration
of PTTG or FGF2 content. Pituitary angiogenesis correlates with pituitary hyperplasia and increased prolactin synthesis and release.
for the maximal growth of this mouse model of dopamine
agonist resistant prolactinomas [7]. Local therapy with
VEGF-TRAPor a systemic treatmentwith amonoclonal anti-
body targeting murine VEGF resulted in substantial tumor
and prolactin inhibition in hyperplastic pituitaries from
Drd2−/− female mice. Additionally, there were significant
decreases in vascularization and proliferation index induced
by both anti-VEGF strategies in the pituitary tumors. These
data suggest that the antiangiogenic treatments were effective
in inhibiting the growth of primary dopamine resistant
prolactinomas as well as the transplanted adenomas.
Furthermore, in an aggressive prolactinoma generated in
the multiple endocrine neoplasia 1 mouse model, Mab G6-31,
a monoclonal anti-VEGF antibody, inhibited the growth of
the intracerebrally injected pituitary adenoma and reduced
prolactin levels [92].
In lactotrope hyperplasia induced by a synthetic estrogen,
treatment with ABT-510 and ABT-898, two thrombospondin
8 International Journal of Endocrinology
analogs with antiangiogenic properties, counteracted pitu-
itary size and serum prolactin increase, and decreased tumor
vasculature [47].
Curcumin (diferuloylmethane), a polyphenolic com-
pound derived from the spice plant Curcuma longa, displays
multiple actions on solid tumours including antiangiogenic
effects. Curcumin dose-dependently inhibited basal VEGF
secretion in corticotrope AtT20mouse and lactosomatotrope
GH3 rat pituitary tumour cells as well as in human pituitary
adenoma cell cultures [93] indicating its potential as an
antiangiogenic agent in pituitary adenomas.
In humans, antiangiogenic therapy was used in the
treatment of an aggressive pituitary tumor. An aggressive
silent corticotrope cell pituitary adenoma, subtype 2, that
progressed to carcinoma despite temozolomide administra-
tion was treated with the anti-VEGF monoclonal antibody
bevacizumab for 26 months with stabilization of disease as
documented on serial MRI and PET scans [94].
The present findings in murine animal models and
humans suggest that antiangiogenic therapy may represent
a complementary option in the treatment of aggressive
pituitary tumors.
6. Conclusions
In pituitary adenomas an altered expression of angiogenic
growth factors and their receptors has been observed [48, 57,
95–97]. Although it is unlikely that these alterations play a
causative role in pituitary tumor pathogenesis, intratumoral
changes of these factors and their receptors may result in a
permissive microenvironment that contributes to excessive
hormone production and loss of growth control in pituitary
adenomas.
Each pituitary tumor of clonal origin represents the
multifactorial result of failure of different regulatory events.
In this regard, pro- and antiangiogenic growth factors, such
as FGF-2, VEGF, and others, may determine the final angio-
genic phenotype of pituitary tumors and thus subsequent
tumor behavior. Furthermore, the study of angiogenic factor
expression in aggressive prolactinomas with resistance to
dopamine agonists will yield important data in the search of
therapeutical alternatives.
We conclude that angiogenesis is an active process in
these tumors, in spite of their low total vascular area when
compared to nontumoral pituitary. Understanding the role
of angiogenesis in their development may facilitate therapeu-
tical management in the cases of adenomas that cannot be
controlled by conventional therapy.
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